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Parkinson’s disease (PD) is characterized by the progressive degeneration of neurons in the substantia nigra pars compacta (SN).
The na¨ ıve SN is highly susceptible to inﬂammation. In addition, microglial activation in the degenerating SN displays distinct
characteristics that increase the reactivity of the region towards inﬂammatory stimuli. On the other hand, gene therapy for PD
has recently move forward into clinical settings, with PD being the neurodegenerative disorder with the highest number of Phase
I/II gene therapy clinical trials approved and completed. These clinical trials are not targeting the SN, but this region is a certain
candidateforfuture genetherapy interventions.Here,theuniqueimmune-related properties ofthedegenerating SNinthecontext
of a putative gene therapy intervention are reviewed. Several variables aﬀecting the host response to gene delivery such as vector
type and dosage, age and stage of disease of patients, and method of gene delivery and transgene used are discussed. Finally,
approaches to diminish the risk of immune-mediated toxicity by gene transfer in the SN are presented.
1.Introduction
Parkinson’s disease (PD) is a neurodegenerative disorder
characterised by the progressive loss of dopaminergic neu-
rons in the substantia nigra pars compacta (SN) (reviewed
in [1]). The aetiology of the most common forms of PD
remains unknown. Current therapeutic treatments comprise
pharmacologicalstrategiestocompensatefordopaminedeﬁ-
ciency or surgical interventions that reduce the hyperactivity
of speciﬁc regions within the basal ganglia (reviewed in [2]).
However, dopamine replacement can lead to undesired side-
eﬀects 5–10 years after the beginning of treatment [3]. As no
treatment is available that can prevent disease progression,
the search for new therapeutic interventions is intense. In
particular,genetherapyapproacheshavesuccessfullyreached
the clinical trial stage in a number of cases [4]. Approved
gene therapy clinical trials are based on restoring the activity
of the basal ganglia by providing growth factors, inhibiting
hyperactive regions, or enhancing dopamine synthesis [4].
Viral gene delivery seems to be the method of choice
for gene therapy for PD due to its high eﬃciency for gene
transduction. A drawback to the delivery of genes via viral
vectors comes by introducing an antigenic load into the
brain. These antigens will invariably elicit a transient innate
immune response [5]. The nature and functional (toxic or
protective) consequences of this response will vary depend-
ing on a number of variables but of utmost importance is
the region of gene transfer, the viral dose used, and the state
of microglial activation in that region [5]. Importantly, the
SN is highly susceptible to the toxic eﬀects of inﬂammation
[6, 7]. In addition, microglial activation during neurodegen-
eration in this region possesses particular features that could
exacerbatediseaseprogressionifaproinﬂammatory stimulus
hits the SN [8].
This paper will focus on the properties of microglial
activation in the degenerating SN in PD. In addition, the
immune reaction after gene delivery by adenoviral, adeno-
associated, and lentiviral vectors in the CNS will be dis-
cussed. Finally, a list of risk factors and parameters that
could be considered when assessing the possible inﬂuence
of gene transfer to the SN is presented as well as alternative
approaches to circumvent inﬂammation-mediated toxicity.2 Parkinson’s Disease
2.InﬂammationintheCentralNervous System
Inﬂammation in the Central Nervous System (CNS) has dif-
ferent features according to (i) the region in which it occurs,
(ii)thestimulus,and(iii)themolecularandcellularmilieuat
the time of the response. For example, inﬂammation in the
brain parenchyma is usually restricted to certain leukocyte
populations, harder to initiate, and less widespread than
inﬂammation when itoccurs intheventricles,meninges, and
choroid plexus [9]. At these sites the characteristics are more
reminiscent of a typical systemic inﬂammatory response.
This diﬀerence is mainly due to the absence of dendritic
cells, conventional lymphatics, the downregulation of major
histocompatibility complex (MHC) molecules within the
CNS parenchyma, and the presence of local immunosup-
pressive factors (reviewed in [4, 9–11]). In addition, the
innate inﬂammatory response in the CNS parenchyma does
not always lead to an activation of the adaptive arm of the
immune system (reviewed in [12]).
By origin and function, microglial cells can be regarded
as the resident macrophages of the brain and are the main
innate immune cells in the CNS. Microglial activation is
a highly dynamic process [13–15] and involves phenotypic
and reversible transitions that have been categorized into at
least 4 stages according to Kreutzberg [16]( s e eF i g u r e1).
Microglialactivationisapatho-physiologicalfeatureofmany
brain diseases and for many years its key function was
thoughttobesolely theremoval ofcellulardebris[13].Over-
whelming evidence now shows that microglial activation is
a phenomenon actively involved in neurodegeneration or
neuroprotection (reviewed in [13, 17]).
Despite the many diﬀerences among animal models of
PD and among PD patients, a common feature found in the
SN in PD is the presence of microglial activation (reviewed
in [13, 17–20]). Since the ﬁrst description of microglial
activation in the SN of PD brains by McGeer and colleagues
in1988[21],numerousstudies(morethan30)haverepeated
thisobservationinanimal modelsand PDpatients(reviewed
in [13, 19]). Microglial-secreted factors that are associated
with PD pathology include Interleukin-(IL) 1β,T u m o r
necrosis Factor α (TNF), IL-6, IL-2, Interferon-γ (IFN-γ),
prostaglandins, andreactive oxygenandnitrogen species(for
a comprehensive review see [22]). This is unlike astrogliosis,
which is not as pronounced nor so consistently present
in PD patients or animal models [23, 24]. Therefore, the
discussion will be focused on microglial activation. The role
of astrocytes in PD has been recently discussed in [19].
3.Microglial Activationand PD-Animal Models
In the 6-OHDA model of nigrostriatal neurodegeneration,
microglial activation in the SN was morphological deﬁned
as stage II and III, but not IV [24], see Figure 1.D u r -
ing the neurodegenerative process, transcription but not
translation of key proinﬂammatory cytokines, was markedly
increased [24].In this wayno proinﬂammatory environment
was generated as a consequence of neuronal cell death.
Therefore, microglial activation during neurodegeneration
is not associated with the production of a proinﬂammatory
milieu, as previously presupposed [8, 24]. This observation
concurs with the physiological role of macrophages during
the clearance of apoptotic cells in the periphery where such
macrophageactivationdoesnot promoteinﬂammation [25].
Anexampleofthiswouldbetheclearanceofneutrophils:itis
estimated that 1010 neutrophils/day enter apoptosis and that
macrophages are responsible for removing them in humans.
Were this process to be proinﬂammatory, the human body
would be permanently inﬂamed. In PD, most if not all
neuronal loss in the SN is supposed to be apoptotic [26]a n d
thus, eventhough activated microglia are essential to remove
neuronalcelldebris,aproinﬂammatory milieushouldnotbe
expected from this activation.
Activated microglial cells with higher proinﬂammatory
cytokine mRNA but not protein expression have been
described as being in a “primed” state, ready to produce an
outburst of proinﬂammatory cytokines if a second stimulus
appears (see Figure 1). Indeed, it has been demonstrated
that if a subtoxic dose of a proinﬂammatory stimulus, such
as bacterial endotoxin, is delivered to the degenerating SN,
the translation of increased levels of mRNA coding for IL-1
takes place and an intense proinﬂammatory environment is
generated [8]. Interestingly, this eﬀect can also be elicited
systemically by the sustained expression of circulating IL-1
[8]. Of utmost importance was the observation that this
displacement of the equilibrium towards a proinﬂammatory
milieu in the SN exacerbated disease progression and
triggered earlier and more pronounced motor signs [8]
(see Figure 1). Reversing the order of the stimuli could
lead to a similar or a diﬀerent observation. It has been
described that previous exposure to LPS rendered the
animals more susceptible to the neurotoxic eﬀects of 6-
OHDA [27]. On the other hand, the prior inoculation of
IL-1 has a neuroprotective eﬀects on the nigral neurons
[28]. In addition, if this preexposition to inﬂammation was
performed during pregnancy, the adult oﬀspring were not
only more susceptible to 6-OHDA administration, but had
fewer dopaminergic cells in the SN at postnatal day 10
compared to controls [29, 30].
Neurons in the SN have been shown to be particularly
susceptible to microglial-mediated toxicity in vitro and
in vivo [6, 7], and anti-inﬂammatory interventions have
been shown to be neuroprotective in animal models of
PD [31–35]. By contrast, some early work has reported
neuroprotective eﬀectsof inﬂammatory mediators. Variables
such as duration and amount of expression of a speciﬁc
cytokineseem to be important to anticipate the ﬁnal eﬀectof
agivencytokineonneuronalviability.Forexample,theacute
injection of IL-1β in the SN was not toxic for dopaminergic
neurons in vivo if the cytokine was injected alone (10ng
or 1000 Units) or in combination with 1000 Units of TNF
and 100 Units of IFN-γ in the SN [36, 37]. If, however,
the expression of IL-1 or TNF in the SN was sustained
between 14 and 21 days, it caused neuronal death, motor
symptoms, and microglial activation to Stage IV [38–40].
Similarly, long-term inhibition of IL-1 or TNF attenuated
loss of dopaminergic neurons in PD models [8, 41–43].
It can be concluded from these data that dosage and
duration of expression are important to predict an eﬀect ofParkinson’s Disease 3
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Figure 1: Schematic representation of the interactions between microglial activation and gene transfer. During neuronal death, microglial
cells are activated to a “primed” state, where no proinﬂammatory cytokines are secreted. After receiving an additional (proinﬂammatory)
stimulus, microglia activation changes into an exacerbated proinﬂammatory state that leads to increased neurodegeneration. Depending on
variables such as type and dosage of vector used, inoculation of viral vectors might provide this second proinﬂammatory stimulus.
a given cytokine on neuronal viability in the SN. However,
some univocal eﬀects could be deﬁned. For example, if a
subtoxic inﬂammatory stimulus is present in the degener-
ating SN where “primed” microglia are present, neuronal
death could be exacerbated. Similarly, if the expression of
IL-1orTNFin theSNatproinﬂammatory levelsissustained,
neuronal cell death is likely to occur.
4.Microglial Activationand PD-ClinicalData
As explained above, microglial activation has been found in
the SN of PD patients (reviewed in [13, 19]) in postmortem
tissue sample and also by noninvasive imaging [20, 44]. In
addition, higher expression levels of IL-1, IL-2, IL-6, and
TNF were found in striatal postmortem samples of PD
patients[45–47].Usingtheperipheralbenzodiazepinerecep-
tor as ligand (PK-11195) in a positron emission tomography
study,neuroinﬂammatory processeshavebeenveriﬁedinthe
pons, basal ganglia, and frontal cortex of PD patients [44].
The resolution of this technique has not allowed an accurate
study of the SN. It should also be noted that evidence
from PD patients indicates that microglial activation is not
restricted to the SN, but it can also involve the putamen,
hippocampus, brainstem,andcingulateandtemporalcortex
[44, 48].
5.Possible Effectsof Inﬂammation-Eliciting
Gene Transferonthe DegeneratingSN
Viral gene delivery will introduce an antigenic load into the
brain [49]. These antigens will invariably elicit at least, a
transient innate immune response [49]. As stated before,
in a na¨ ıve CNS, the innate immune response can be
dissociated from the adaptive immune response in the brain
parenchyma; for example, the systemic immune system can
remain ignorant of a ﬁrst antigenic challenge into the brain
parenchyma. However, what happens if this viral load hits a
brain region in which on-going inﬂammation or “primed”4 Parkinson’s Disease
microglial activation (as most likely will occur in the SN
of PD patients) is present? Several variables need to be
consideredtoanswer thiscomplexquestion,includingvector
type,vectordosage,methodofdelivery,patients’age,stageof
disease progression, and transgene used.
5.1. Vector Type and Dosage. The three main types of vector
that emerge as solid candidates for gene therapy clinical
trials for PD are adenoviral, adeno-associated, and lentiviral
vectors.
Adenoviral vectors are among the most studied vectors
for gene delivery in the CNS. In particular, the immune
response to this virus in the brain has been extensively inves-
tigated. First-generation adenoviral vectors (Fg-Ad) allow
transgene expression in the na¨ ıve brain for up to one year,
which appears to be independent of a transient and initial
inﬂammatory response [8, 12, 38, 39, 49–53]. However,
preexisting or subsequent systemic immune response to
adenovirus in the host abolish, or at least reduce by half, the
transgene expression and can lead to cytotoxicity ([49–52],
reviewed in [5, 11]). Direct inoculation of 5 × 106 − 1 × 107
infective particles of control adenovectors in the SN, caused
between 10–25% of neurodegeneration per se [39, 40], reen-
forcing the idea of an increased susceptibility of this region
to inﬂammation. As is the case with any viral vector, dosage
determinestheresponsedetectedaftervectoradministration.
Athreshold ofmorethan 107 infectiveparticles ofadenoviral
vectors in the periphery was determined to be needed
to eliminate transgene expression in the brain [52]. This
drawback is not seen when high capacity adenoviral vectors
(hc-Ad) are used for gene transfer in the CNS. Therefore,
hcAd seem to be better vectors for gene transfer in the
brain than Fg-Ad. Nevertheless, the viral capsid is identical
for both vectors and will elicit a response that, within a
degenerating SN, may cause an increase in inﬂammation
with toxic eﬀects. In addition, internalized adenoviral DNA
activates an inﬂammasome-dependent maturation of pro-
I L - 1t ot h ea c t i v ef o r mo fI L - 1i nm a c r o p h a g e s .T h u s ,i ti s
not unlikelythat any type ofadenoviral vectorinjected in the
degenerating SN will contribute to drive the environment to
a proinﬂammatory milieu [54].
Adeno-associated vectors (AAV) are the vectors of choice
for the vast majority ofgene therapy clinicaltrials against PD
[4]. The intrastriatal injection of relatively low titers of AAV
(2 − 4 × 108 i.p.) in na¨ ıve animals provokes a low innate
immune response with no mononuclear cell inﬁltrate or
cuﬃng of nearby blood vessels [55, 56]. However, at higher
doses, a transient but signiﬁcant astrogliosis can be detected
[57]. In addition, in animal models previously exposed
to systemic AAV, immunization inhibited AAV serotype 2
(AAV-2)gene transfer inthe CNS[56], and readministration
ofAA Vi nth ebra i ni n duc edagr ea t eri n ﬂ a m m a t oryr es pon s e
[56, 58].
Results from Phase I and II clinical trials for PD
have not reported severe adverse eﬀects related to AAV
administration [59–63]. Gene transfer was performed in
the putamen or in the subthalamic nucleus. Despite these
encouraging results, long-term analysis of a bigger cohort
is needed to provide robust data on the degree of safety
of these vectors during gene transfer in the brain. Unfor-
tunately, the possible toxic eﬀects of inﬂammation that
could mask the potential beneﬁcial eﬀect of the treatment
were apparently not studied. Recently, a Phase I/II clinical
trial has been approved to inoculate patients with AAV
vectors expressing neurturin not only in the putamen,
but also in the SN (http://www.ClinicalTrials.gov identiﬁer:
NCT00985517). According to the data on the susceptibility
oftheSNtoinﬂammation discussedabove,it willbevaluable
to study the inﬂammatory response to the treatment in each
patient to draw conclusionson safety and possibly eﬃcacyin
this trial.
Lentiviral vectors have been approved as vehicles for
clinical gene transfer of aromatic amino-acid decarboxy-
lase, Tyrosine Hydroxylase (TH) and GTP-cyclohydrolase
1, all three genes necessary for dopamine synthesis [64].
Stimulation of dendritic cells by lentiviral vectors is weak
compared with other single-stranded RNA viruses [65]. In
addition,areducedimmuneresponse hasbeendetectedafter
brain administration of multiple-deleted lentiviral vectors
[66]. Worryingly, time-and dose-dependent downregulation
of TH, the rate limiting enzyme in dopamine synthesis,
has been reported after lentiviral-delivery of neurturin [67].
In addition, in the periphery, lentiviral delivery of reporter
genes into the lung triggered T-cell mediated immune
responses against thetransgene [68].Resultsfromthe above-
mentioned clinical trial are awaited to verify the seem-
ingly low-level immune response against lentiviral vectors
in the brain. Finally, the phenomenon of gene silencing
that depends of vector and promoter used and state of
diﬀerentiation of the target cell should be considered [69].
For example, it could be tempting to try to compensate loss
of expression by gene silencing with increased dosage of
vector administered, increasing the probability of eliciting a
proinﬂammatory response and therefore toxic eﬀects on the
SN.
5.2. Method of Gene Delivery. Independently of the vector
of choice, the method of gene delivery may dramatically
inﬂuence the magnitude and characteristics of the immune
reaction against the gene delivery. For example, it is crucial
that the method of vector delivery is accurate enough to
prevent antigens from reaching the brain ventricular system
and the deep cervical lymph nodes so as to keep the systemic
immunesystemignorantoftheantigenicchallengeproduced
by gene delivery in the CNS [5]. If this cannot be achieved,
a systemic immune reaction against the viral vector and/or
transgene delivered is likely to be generated [5]. At the very
least, it will foreshorten the temporal expression proﬁle and,
atworstitwill promoteneurotoxicimmune-mediated eﬀects
in the brain (reviewed in [11]). In conclusion, a delivery
method of high accuracy is needed to prevent antigen
diﬀusion into undesired brain regions.
5.3. Age and Disease Progression. In parallel, age-related
changes in immune reactivity include enhanced Blood-
Brain Barrier permeability and increased microglial and
astroglial reactivity [70–72]. Therefore, changes in theParkinson’s Disease 5
immune response against viral gene transfer can be expected
in a manner that is dependent on the age of the treated
subject.
L-Dopa therapy is quite eﬀective in the early stages of
most PD patients. Therefore, most clinical trials, including
those related to gene therapy, are usually target to late-
stage PD patients. It has been proposed that neuroprotective
strategies will not be beneﬁcial to these patients since
at that stage of the disease there are limited amounts
of dopaminergic neurons to protect. Likewise, late-stage
PD patients will have encountered more opportunities for
neuroinﬂammation in the SN to start and therefore have a
higherrisk of vector-mediatedtoxicityby genetransfer in the
SN.
5.4. Transgene Used. Immune responses against the trans-
gene are not infrequent and depend on whether there has
beenapriorexposuretoitandwhetheritissyn-orxenogenic
to the host [11]. In addition, it should also be borne in
mind that chronic inﬂammation can facilitate dendritic
cell inﬁltration into the CNS, which can facilitate antigen
presentation to na¨ ıve T cells [73]. Again this is a plausible
s i t u a t i o ni nt h ed e g e n e r a t i n gS N .
6.HowCanAll TheseRisksBe Minimized?
A better understanding of the immunological component of
the SN in PD patients together with studies on the possible
beneﬁcial eﬀectsof complementary anti-inﬂammatory treat-
ments, changes in vector serotype, novel chemical formu-
lations, and novel vector design will all help to design the
best scenario to avoid undesired eﬀects of an inﬂammatory
response to gene delivery in the CNS. Alternatively, taking
advantage of certain intrinsic properties of viral vectors
might help to circumventthe risk of inﬂammation in theSN.
For example, vectors can be used for the retrograde delivery
of genes (e.g., adenoviral vectors could be administered in
the striatal terminals of nigral neurons to deliver genes in the
SN [38]). Certainly, this strategy has the disadvantage that it
can reduce the amount of transgene delivered to the SN as
seems to be the case in the Phase II trial with AAV-neurturin
[63]. Nevertheless, it is a useful strategy to be considered
when planning future gene therapy strategies using diﬀerent
vectors or transgenes. In addition, analyzing risk factors for
each treatment and patient (age, method of gene delivery,
immunogenicity of vector used, immunological status of
the brain area to treat, inﬂuence of the transgene to be
transferred, dosage, previous exposure to the virus used as
vector) will certainly reduce the risk of immune-derived
toxicity during gene transfer protocols against PD. In the
future, this immunological risk analysis could even be
used as an inclusion or exclusion criterium. Unfortunately,
nowadays knowledge is still lacking to deﬁne parameters
with univocal eﬀects on the immunological response of
gene transfer into the SN, and technology is behind to
determine the immunological status of the SN at the time of
gene transfer. Therefore, the most reasonable measurement
is to design a clinical trial protocol to reduce the risk of
inﬂammation-mediated toxicity as much as possible.
For example, we would like to propose that if a con-
stellation of risk factors (increased age, late stage of disease,
previous exposed to the virus, high viral dose) is present,
an anti-inﬂammatory therapy could be considered [44].
Anti-inﬂammatory treatments such as COX-2 inhibition,
minocycline, and naloxone have promising eﬀects on ani-
mal models of PD [31–35]. In the context of a possible
inﬂammatory reaction in a gene therapy protocol in the
SN, these anti-inﬂammatory treatments may be reconsid-
ered as complementary treatments. In addition, not only
conventional anti-inﬂammatory therapies could be helpful
to reduce the inﬂammatory risk of a PD patient, but anti-
inﬂammatory molecules could be delivered by gene transfer
in addition to other therapeuticgenes. In particular, the viral
delivery of Interleukin-10 or IL-1ra has been shown to be
neuroprotective in the 6-OHDA rat model of PD [8, 74].
7.Conclusions
The SN is the main area of neurodegeneration in PD.
Microglialactivation andproinﬂammatory cytokineproduc-
tion have special characteristics in the degenerating SN that
shouldnotbeunderestimatedwhendesigningagenetransfer
protocol in that area. It is expected that “primed” microglia
or an on-going inﬂammatory response will be present at the
time of gene transfer in PD patients. Numerous variables
are in play that could change the expected outcome of gene
delivery. An exhaustive analysis of the status of risks factors
known to lead to inﬂammation at the moment of clinical
intervention, leading to complementary anti-inﬂammatory
treatments and/or alternative gene delivery strategies or
additional genes delivered (e.g., IL-10) is proposed to reduce
undesired, inﬂammation-driven side eﬀects. Gene therapy
against PD has reached maturity with eight clinical trials
approved.Itisofimportancetoconsider,withthelimitations
of the available technology and knowledge, all variables
aﬀecting the immunological status of the PD patient and the
possible interactions with the inﬂammatory component of
gene delivery. This analysis should increase the probability
of providing safe gene transfer in the SN and reduce
inﬂammation-biased results that can obscure the eﬃcacy of
a given gene transfer protocol.
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